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ABSTRACT
Background: Owing to a lack of evidence, patients
undergoing heart valve surgery have been offered
exercise-based cardiac rehabilitation (CR) since 2009
based on recommendations for patients with ischaemic
heart disease in Denmark. The aim of this study was to
investigate the impact of CR on the costs of healthcare
use and sick leave among heart valve surgery patients
over 12 months post surgery.
Methods: We conducted a nationwide survey on the
CR participation of all patients having undergone valve
surgery between 1 January 2011 and 30 June 2011
(n=667). Among the responders (n=500, 75%), the
resource use categories of primary and secondary
healthcare, prescription medication and sick leave were
analysed for CR participants (n=277) and non-
participants (n=223) over 12 months. A difference-in-
difference analysis was undertaken. All estimates were
presented as the means per patient (95% CI) based on
non-parametric bootstrapping of SEs.
Results: Total costs during the 12 months following
surgery were €16 065 per patient (95% CI 13 730 to
18 399) in the CR group and €15 182 (12 695 to
17 670) in the non-CR group. CR led to 5.6 (2.9 to
8.3, p<0.01) more outpatient visits per patient. No
statistically significant differences in other cost
categories or total costs €1330 (−4427 to 7086,
p=0.65) were found between the groups.
Conclusions: CR, as provided in Denmark, can be
considered cost neutral. CR is associated with more
outpatient visits, but CR participation potentially offsets
more expensive outpatient visits. Further studies
should investigate the benefits of CR to heart valve
surgery patients as part of a formal cost-utility
analysis.
INTRODUCTION
With an ageing population, heart valve
disease incidence and number of heart valve
procedures performed are both increasing,1
but the associated economic burden is
sparsely investigated.2 Additionally, over the
past 15 years, the survival and management
of patients with cardiovascular disease has
improved substantially, resulting in a more
complex case proﬁle by the time of heart
valve surgery,3 which may impact the recov-
ery path and healthcare use following
surgery.
Although health-related quality of life
(HRQL) improves following heart valve
surgery,4 difﬁculties resuming normalcy and
physical function, along with anxiety and
depression, can persist.5
A recent Cochrane systematic review on
exercise-based cardiac rehabilitation (CR) to
patients after heart valve surgery identiﬁed
only two randomized trials including a total
of 148 patients. Both trials showed
KEY QUESTIONS
What is already known about this subject?
Even though cardiac rehabilitation is recommended
after heart valve surgery, there is a lack of studies
investigating the economic implications. Several
studies have highlighted the difficulties of imple-
menting results from randomised trials due to struc-
tural differences in settings and large variation in
clinical practice including referral, participation and
adherence rates, among other substantial factors.
What does this study add?
This study examines the cost consequences of
offering cardiac rehabilitation in a national health-
care system with referral rates, participation rates
and programme variation of a real-life setting using
multiple data sources. We find that more than half
of patients in our sample choose to participate in
rehabilitation and that participation is overall cost
neutral to the healthcare system due to provision
costs being outweighed by less costly service use
elsewhere.
How might this impact on clinical practice?
While randomised controlled trials with economic
evaluation conducted alongside remain important
sources for informing future priorities. However,
this study provides important reference values for
how heart valve patients value rehabilitation and
what consequences universal provision has else-
where in a healthcare system and at the labour
market.
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improvements in exercise capacity in favour of CR com-
pared to usual care, but the evidence was inadequate
regarding other outcome measures, such as mortality
and HRQL.6 Due to the lack of evidence, CR has been
offered nationwide to heart valve surgery patients in the
Danish health care system since 2009 based on recom-
mendations for patients with ischemic heart disease7 8
for which CR is shown to reduce hospital admissions,
improve HRQL and, to some extent, reduce total and
cardiovascular mortality.9 Studies are inconsistent on
whether CR participation impacts the rate of return to
work and number of days off work due to sick leave.10 11
Two systematic reviews including economic evaluations
of CR of varying quality have concluded, that CR is cost
effective among patients with myocardial infarction, cor-
onary artery bypass surgery, percutaneous transluminal
angioplasty and heart failure12 13 despite heterogeneity
across studies. No studies have assessed the effect of CR
to heart valve surgery patients from an economic per-
spective. Findings from the existing economic evaluations
may not be applicable to heart valve surgery patients,
since these may have a different cost proﬁle, preferences
and beneﬁt differently from CR participation. Although
the beneﬁcial effects of CR have been demonstrated, par-
ticipation and adherence remain sub-optimal,14 which
may also complicate transfer of ﬁndings to real-life set-
tings from economic evaluations based on the limited
number of randomized trials, which cannot be pooled.12
may not be easily transferred to real-life settings.
The objective of this study was to investigate the
impact of CR, after heart valve surgery, on the costs asso-
ciated with healthcare use and sick leave among con-
secutive patients, based on national practice.
MATERIALS AND METHODS
Study design
This was a 12-month follow-up of a prospective compara-
tive observational study of CR participation versus non-
participation using data acquired from several registers
and merged at the individual level using a Statistics
Denmark server. Information on CR participation was
derived from a nationwide survey.
Population
A cohort of consecutive patients undergoing heart valve
surgery in Denmark between 1 January 2011 and 30 June
2011, and 18+ years of age and not undergoing percutan-
eous valve replacement, was identiﬁed in the National
Patient Register15 using the Danish SKS procedure codes
based on the NOMESCO (Nordic Medico-Statistical
Committee) classiﬁcation of Surgical Procedures: KFG
(tricuspid valve surgery), KFJE and KFJF (pulmonary
valve surgery), KFK (mitral valve surgery) and KFM
(aortic valve surgery) (n=770). Of these, 51 patients had
a research-protected address and 52 died before
December 2011. We invited the remaining 667 patients to
participate in a nationwide postal survey 6–12 months
post surgery on CR participation. The questions on CR
participation, which also included a deﬁnition of CR spe-
cifying the elements of a CR programme, have been
developed and previously tested by the Danish Heart
Association to assess CR participation among patients
with ischemic heart disease.16 A reminder was sent after
two weeks, and the response rate was 500/667 (75%).
Cardiac rehabilitation in Denmark
CR recommendations in Denmark include physical exer-
cise training, psychosocial support, disease education, diet
counselling, smoking cessation sessions and follow-up of
medical treatment and CR initiation approximately 1–2
weeks after surgery and 4-6 weeks for physical exercise
training due to sternal wound recovery.7 8 17
CR programmes are usually provided in outpatient settings
in the hospitals. However, since 2007, municipalities in
Denmark have also been able to provide CR based on the
same recommendations either fully or as a shared pro-
gramme with a hospital. At the time of the survey, 32/34
hospitals had a CR programme, and among the 98 munici-
palities, 11 had a full programme, whereas 30 municipal-
ities participated in a shared programme with a hospital.
The hospital-based programmes lasted 5–24 weeks (mean
11.5). In the municipalities, the programmes lasted 2–12
weeks (mean 8.5). Most exercise training sessions across
programmes were conducted twice weekly.18
Of the 500 patients, 277 (55%) patients reported to
have participated in CR versus 223 (45%) not participat-
ing. Non participation was due to patients not being
referred (18%) and to being referred but choosing not
to participate (27%). The main self-reported reasons for
non-participation were readmissions, comorbidity,
having returned to work, transportation and being in
physical good shape and considering CR unnecessary.
CR participants reported to have received physical
training (277/277, 100%), formal psychosocial support
(81/277, 29%), disease education (144/277, 52%), diet
counselling (169/277, 61%) and follow-up of medical
treatment (219/277, 79%) as part of the CR pro-
gramme. Among smokers 14/48 (29%) had attended
smoking cessation sessions”. Only patients, who had par-
ticipated in a formal programme in either a hospital or
a municipality, were included as CR participants. Among
these, 230 of the 277 patients reported following a full
or shared hospital-based CR programme.
Baseline variables
For baseline assessment, we obtained information
from several registers at Statistics Denmark registers.
Preoperative and postoperative comorbidity was calcu-
lated using the index described by Charlson et al19 for
each patient using the primary and secondary diagnosis
for hospital contacts.
Resource use and costs
The cost analysis included the categories: primary health-
care, secondary healthcare (hospital-based inpatient and
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outpatient visits), prescription medication and produc-
tion loss due to sick leave. All costs were inﬂated to
2012-€ using the general consumer price index and a
currency conversion rate of 745DKK=100€. Costs asso-
ciated with hospital-based CR were included in the cost
parameter of outpatient visits.
Measurement and valuation of healthcare use
Primary healthcare
All contacts in the primary healthcare sector are recorded
in the Danish National Health Service Register for
Primary Care.20 We categorised service providers into four
groups: general practitioners (codes 80-84, 89), medical
specialists (codes 1-21, 23-24), physiotherapists (codes 51,
62) and psychologists (code 63). Resource use in primary
healthcare was valued using the tariffs of national agree-
ments between the professional associations of medical
specialists and the Danish National Health Service.
Secondary healthcare
From the National Patient Register,15 we obtained informa-
tion on hospital admissions and outpatient visits. Resource
use in secondary healthcare was valued using the tariffs of
the case-mix system of diagnosis-related groupings (DRG)
for inpatient services and the Danish Ambulatory
Grouping System (DAGS) for outpatient visits.
Inpatient admissions were divided into acute and non-
acute admissions in departments of cardiology, thoracic
surgery and other departments. Primary diagnoses were
manually veriﬁed for the admissions during the ﬁrst
month postsurgery. Outpatient visits were divided into
cardiology, thoracic surgery and other departments.
Prescription medication
The Danish National Prescription Register includes data
on prescription medication dispensed in Denmark.21
Medications of particular relevance were identiﬁed
using the Anatomical Therapeutic Chemical (ATC) classi-
ﬁcation codes: ACE inhibitors (C09A, C09B), β-blockers
(C07), spironolactone (C03DA01), lipid-modifying
agents (C10A, C10B), digoxin (C01AA05), diuretics
(C03A, C03C), antithrombotic agents except anticoagu-
lant treatment (B01A), anticoagulant treatment (B01AA,
B01AE07, B01AF02, B01AF01), psycholeptics (N05A),
antiarrhythmic drugs (C01BD01, C01BD07) and analgae-
sics (M02, N02). Medication use per patient was calcu-
lated using the deﬁned daily dose (DDD), which is the
assumed average maintenance dose per day of a drug
used for its main indication,22 and valued by the retail
price. Records without DDD values, respectively 810/
25,693 and 997/33,715, presurgery and postsurgery, were
manually reviewed and omitted from the analysis due to
low impact on the results.
Sick leave
Information on sick leave was acquired from the
DREAM database including weekly information on
social beneﬁts, which is administered by the Danish
Ministry of Employment. Only sick leave lasting for more
than 2 weeks is registered in the DREAM database.10 23
Productivity losses due to sick leave were based on
national age-matched and gender-matched gross wages.
Statistical methods
Data were collected 1 year before and 1 year postsurgery,
which allowed for the analysis of (1) within-group differ-
ences over time (costs incurred the year before discharge
minus the costs incurred the year after discharge) and (2)
differences between within-group differences (CR vs no
CR). The purpose of this analytical approach is to adjust
for endogenous variables that do not vary over time (eg,
patient characteristics) and exogenous variables that do
not vary between groups (eg, context of rehabilitation).
Baseline characteristics were analysed using Student
t tests for continuous variables and χ2 tests for categor-
ical variables.
Healthcare utilisation, sick leave and costs were
reported as mean resource use and cost per patient as
well as the differences between them. Non-parametric
bootstrapping with 5000 replications was used to esti-
mate the SEs and 95% CIs due to the usual nature of
resource-use data, which are right-skewed.24 There was
no loss to follow-up.
Statistical analyses were carried out using Stata V.13.
A p value below 0.05 was considered statistically
signiﬁcant.
ETHICS
The study was approved by the Danish Data Protection
Agency (2011-41-6378, 2013-41-1643), and the data were
handled in accordance with the Act on Processing of
Personal Data. Non-interventional studies do not require
approval from ethics committees in Denmark.
RESULTS
Baseline characteristics are described in table 1, with
minor differences between the CR and no CR groups
according to age, marital status and type of surgery.
A statistically signiﬁcant difference in the mean number
of total outpatient visits per patient between groups was
observed, with a higher number of 5.6 (95% CI 2.9 to 8.3,
p<0.01) visits in the CR group (table 2). The difference in
the total number of outpatient visits between groups was
reﬂected in a non-statistically signiﬁcant difference in
costs, with higher costs per patient in the CR group of
EUR 407 (−378; 1,191, p=0.29) (table 3). Of the total
number of outpatient visits in the CR group, 8.6 (7.5 to
9.6) visits per patient were due to physical exercise training
as part of the CR programme (data not shown). The dif-
ference in the total number of outpatient visits between
groups was reﬂected in a non-statistically signiﬁcant differ-
ence in costs, with higher costs per patient in the CR
group of €407 (−378 to 1191, p=0.29; table 3).
Except for differences in the number of outpatient
visits, we found no statistically signiﬁcant differences in
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Table 1 Baseline characteristics of consecutive patients eligible for exercise-based cardiac rehabilitation after heart valve surgery
Total
population
(n=667)
Responders
(n=500)
Non-responders
(n=167) p Value
CR group
(n=277)
No CR group
(n=223) p Value
Age 68.4 (12.5) 69.2 (12.0) 66.0 (13.6) <0.01 68.2 (11.9) 70.5 (12.0) 0.04
Male 423 (63.4) 327 (65.4) 96 (57.5) 0.07 186 (67.2) 141 (63.2) 0.35
Married 411 (61.6) 323 (64.6) 88 (52.7) <0.01 195 (70.4) 128 (57.4) 0.02
Labour market attachment
Employed 152 (22.8) 116 (23.2) 36 (21.6) 65 (23.5) 51 (22.9)
Unemployed 14 (2.1) 6 (1.2) 8 (4.8) <0.01 5 (1.8) 1 (0.4) 0.61
Retired 445 (69.7) 344 (68.8) 101 (60.5) 191 (69.0) 153 (68.6)
Educational level
Maximum of 9 school years 277 (41.5) 207 (41.4) 70 (41.9) 114 (41.2) 93 (41.7)
High school, vocational training 264 (39.6) 200 (40.0) 64 (38.3) 0.09 112 (40.4) 88 (39.5) 0.70
University degree 103 (15.4) 77 (15.4) 26 (15.6) 48 (17.3) 29 (13.0)
Missing 23 (3.4) 16 (3.2) 7 (4.2) 3 (1.1) 13 (5.8)
Annual income (€)
0–20 000 295 (44.2) 206 (41.2) 89 (53.3) 102 (36.8) 104 (46.6)
20 000 –30 000 209 (31.3) 160 (32.0) 49 (29.3) <0.01 95 (34.3) 65 (29.1) 0.09
≥30 000 163 (24.4) 134 (26.8) 29 (17.4) 80 (28.9) 54 (24.2)
Type of surgery
Aortic valve 519 (77.5) 392 (78.4) 127 (76.0) 0.54 208 (75,1) 184 (82.5) 0.04
Mitral valve 159 (25.2) 123 (24.6) 36 (21.6) 0.41 74 (26.7) 49 (22.0) 0.22
Tricuspid valve 10 (1.5) 7 (1.4) 3 (1.8) 0.72 5 (1.8) 2 (0.9) 0.39
Pulmonal valve 11 (1.6) 6 (1.2) 5 (3.0) 0.11 4 (1.4) 2 (0.9) 0.58
Concomitant CABG 203 (31.3) 152 (30.4) 51 (30.5) 0.91 89 (32.1) 63 (28.3) 0.31
Cardiac history
Previous heart valve surgery 4 (0.6) 3 (0.6) 1 (0.6) 0.92 2 (0.7) 1 (0.4) 0.69
Previous CABG 20 (3.0) 13 (2.6) 7 (4.2) 0.30 7 (2.5) 6 (2.7) 0.91
Previous MI 83 (12.4) 51 (10.2) 32 (19.2) <0.01 29 (10.5) 22 (9.9) 0.78
Heart failure 136 (20.4) 92 (18.4) 44 (26.3) 0.02 46 (16.6) 46 (20.6) 0.21
Cerebrovascular disease 59 (8.8) 43 (8.6) 16 (9.6) 0.71 28 (10.1) 15 (6.7) 0.17
Arrhythmia 226 (33.9) 173 (34.6) 53 (31.7) 0.70 105 (37.9) 68 (30.5) 0.08
Comorbidity
Renal Disease 32 (4.8) 23 (4.6) 9 (5.4) 0.74 15 (5.4) 8 (3.6) 0.74
COPD 68 (10.2) 42 (8.4) 26 (15.6) <0.001 27 (9.7) 15 (6.7) 0.16
Diabetes mellitus 74 (11.1) 53 (10.6) 21 (12.6) 0.53 26 (9.4) 27 (12.1) 0.32
Charlson comorbidity index score 1.0 (1.4) 0.9 (1.3) 1.3 (1.6) <0.01 0.9 0.9 0.92
Values are number of patients (%) for categorical variables and mean (SD) for continuous variables.
p Values are derived from χ2 test for categorical variables and student’s independent samples t test for continuous variables.
CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; CR, cardiac rehabilitation; MI, myocardial infarction.
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Table 2 Healthcare resource utilisation and sick leave 12 months before and after exercise-based cardiac rehabilitation following heart valve surgery
CR group (n=277) No CR group (n=223) Difference between
group differenceBefore After Difference Before After Difference p Value
Primary care (visits)
General practitioners 15.7 (0.7) 25.3 (0.9) 9.6 (0.8) 17.1 (0.8) 27.1 (1.1) 10.1 (0.9) 0.5 (−2.9 to 1.9) 0.67
Medical specialists 0.5 (0.0) 0.5 (0.0) 0.0 (0.0) 0.5 (0.3) 0.5 (0.5) 0.0 (0.3) 0.0 (−0.1 to 0.0) 0.06
Physiotherapists 0.1 (0.1) 0.1 (0.0) 0.0 (0.0) 0.1 (0.0) 0.1 (0.0) 0.0 (0.0) 0.0 (0.0 to 0.0) 0.20
Psychologists 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0 to 0.0) 0.68
Other 0.8 (0.0) 0.8 (0.0) 0.0 (0.0) 0.8 (0.0) 0.8 (0.0) 0.0 (0.0) 0.0 (0.0 to 0.1) 0.78
Total 17.2 (0.7) 26.7 (0.9) 9.5 (0.9) 18.5 (0.8) 28.7 (1.1) 10.2 (0.9) −0.6 (−3.1 to 1.8) 0.60
Hospital inpatient (admissions)
Cardiovascular, acute 0.6 (0.1) 0.3 (0.1) −0.2 (0.1) 0.6 (0.1) 0.4 (0.1) −0.1 (0.1) −0.1 (−0.3 to 0.1) 0.27
Cardiovascular, not acute 0.5 (0.0) 0.1 (0.0) −0.4 (0.0) 0.5 (0.0) 0.1 (0.0) −0.4 (0.0) 0.1 (−0.1 to 0.2) 0.78
Thoracic surgery acute 0.1 (0.0) 0.0 (0.0) −0.1 (0.0) 0.1 (0.0) 0.1 (0.0) 0.0 (0.0) −0.1 (−0.1 to 0.0) 0.22
Thoracic surgery not acute 1.0 (0.0) 0.0 (0.0) −1.0 (0.0) 1.0 (0.0) 0.0 (0.0) −1.0 (0.0) 0.0 (−0.1 to 0.1) 0.71
Other, acute 1.1 (0.1) 0.7 (0.1) −0.4 (0.1) 1.4 (0.1) 1.0 (0.1) −0.4 (0.2) −0.1 (−0.4 to 0.3) 0.69
Other, not acute 0.4 (0.0) 0.2 (0.0) −0.1 (0.1) 0.3 (0.0) 0.2 (0.0) −0.2 (0.1) 0.1 (−0.1 to 0.2) 0.26
Total 3.6 (0.1) 1.4 (0.1) −2.2 (0.1) 4.0 (0.2) 1.8 (0.2) −2.2 (0.2) −0.1 (−0.6 to 0.4) 0.80
Bed days 21.9 (1.1) 5.9 (0.8) −15.9 (1.1) 24.3 (1.5) 7.2 (1.0) −17.1 (1.7) 1.2 (−2.9 to 5.2) 0.57
Hospital outpatient (visits)
Cardiology 3.0 (0.2) 5.3 (0.6) 2.4 (0.6) 2.5 (0.2) 3.8 (0.5) 1.3 (0.5) 1.0 (−0.5 to 2.6) 0.19
Thoracic surgery 0.2 (0.1) 1.3 (0.2) 1.1 (0.2) 0.3 (0.0) 0.7 (0.1) 0.3 (0.1) 0.8 (0.3 to 1.3) <0.01
Other 6.7 (0.7) 12.6 (0.9) 6.0 (0.7) 6.0 (0.4) 8.2 (0.9) 2.2 (0.8) 3.8 (1.6 to 5.9) <0.01
Total 9.9 (0.8) 19.3 (1.0) 9.4 (0.9) 8.8 (0.5) 12.7 (1.1) 3.9 (1.0) 5.6 (2.9 to 8.3) <0.01
Prescription medication (DDD)
Ace-inhibitors 145.6 (17.9) 248.9 (25.2) 103.3 (22.2) 148.1 (19.5) 222.9 (25.8) 74.8 (22.6) 28.4 (−31.7 to 88.6) 0.35
Antithrombotic 175.2 (12.0) 267.8 (14.2) 92.6 (14.8) 158.9 (13.2) 263.9 (14.0) 105.0 (16.4) −12.4 (−55.7 to 31.0) 0.58
β-blockers 51.7 (5.5) 132.2 (8.1) 80.5 (7.8) 53.4 (6.2) 113.7 (8.9) 60.3 (8.0) 20.2 (−1.6 to 42.1) 0.08
Spironolactone 6.5 (1.9) 14.7 (2.7) 8.2 (2.5) 8.3 (2.1) 17.9 (3.4) 9.6 (3.4) −1.4 (−9.4 to 6.8) 0.74
Lipid modifying 62.4 (13.5) 115.9 (18.8) 53.5 (13.6) 59.3 (16.7) 118.7 (24.9) 59.4 (18.6) −5.9 (−50.4 to 38.7) 0.79
Digoxin 12.5 (3.7) 16.2 (3.5) 3.6 (4.6) 11.4 (3.5) 18.8 (3.9) 7.3 (3.8) −3.7 (−15.5 to 8.0) 0.54
Diuretics 271.2 (62.1) 350.8 (37.8) 79.5 (66.0) 219.3 (51.9) 344.8 (30.8) 125.5 (52.0) −46.0 (−211.2 to 119.3) 0.58 0.58
Vitamin K antagonists 31.8 (4.1) 124.8 (8.7) 93.0 (8.7) 34.2 (5.1) 112.0 (8.8) 77.8 (8.8) 15.2 (−9.1 to 39.6) 0.22
Psycholeptics 0.5 (0.5) 0.5 (0.5) 0.00 (0.0) 1.8 (0.9) 1.8 (0.9) 0.0 (0.0) 0.0 (−2.5 to 2.5) 1.00
Antiarrythmics 7.1 (2.0) 33.5 (5.0) 26.3 (4.7) 9.1 (1.1) 26.7 (5.2) 17.6 (5.6) 8.7 (−5.8 to 23.2) 0.24
Analgetics* 32.6 (5.4) 46.6 (6.2) 14.4 (3.0) 47.2 (7.8) 67.0 (8.5) 19.9 (5.6) −5.4 (−18.0 to 7.2) 0.39
Other cardiovascular 238.5 (20.8) 254.2 (21.9) 15.7 (22.8) 238.8 (25.4) 241.2 (22.8) 2.3 (21.4) 13.4 (−47.5 to 74.3) 0.67
Other medication 553.4 (32.8) 704.2 (33.0) 150.8 (23.2) 609.1 (40.9) 817.5 (47.4) 208.4 (27.8) −57.6 (−128.1 to 12.9) 0.11
Total 1588.6 (99.9) 2310.3 (80.2) 721.7 (96.6) 1599.0 (100.0) 2367.0 (93.2) 768.0 (78.2) −46.2 (−287.2 to 195.5) 0.71
Sick leave (weeks) 1.4 (0.3) 4.8 (0.7) 3.4 (0.6) 1.2 (0.3) 3.5 (0.7) 2.4 (0.5) 1.0 (−0.6 to 2.7) 0.21
Values are mean number of visits/amounts and associated SE 1 year presurgery and postsurgery.
*Includes analgetics and topical products with DDD value for joint and muscular pain.
CR, cardiac rehabilitation, DDD, defined daily doses.
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Table 3 Costs of care 12 months before and after exercise-based cardiac rehabilitation following heart valve surgery
CR group (n=277) No CR group (n=223) Difference between
group differenceBefore After Difference Before After Difference p-Value
Primary care (visits)
General practitioners 337 (17) 544 (23) 207 (22) 352 (17) 569 (25) 217 (22) −10.0 (−70 to 50) 0.74
Medical specialists 153 (21) 113 (14) −40 (18) 136 (17) 125 (16) −11 (23) −29 (−87 to 28) 0.31
Physiotherapists 26 (8) 26 (10) 0 (0) 51 (25) 38 (16) −13 (17) 13 (−22 to 48) 0.46
Psychologists 3 (2) 8 (4) 5 (5) 2 (1) 6 (3) 4 (3) 1 (−10 to 11) 0.93
Other 93 (6) 81 (6) −12 (6) 83 (6) 78 (6) −5 (7) −7 (−24 to 11) 0 47
Total 612 (30) 773 (32) 161 (32) 624 (41) 817 (35) 193 (37) −32 (−126 to 61) 0.51
Hospital inpatient (admissions)
Cardiovascular, acute 3655 (814) 1656 (392) −1999 (828) 3532 (914) 1862 (312) −1670 (897) −329 (−2732 to 2072) 0.78
Cardiovascular, not acute 1438 (151) 675 (243) −763 (273) 1931 (308) 848 (294) −1083 (399) 320 (−616 to 1258) 0.51
Thoracic surgery, acute 3798 (813) 469 (314) −3329 (837) 2950 (818) 446 (196) −2504 (847) −825 (−3158 to 1508) 0.48
Thoracic surgery, not acute 28 902 (904) 251 (136) −28 651 (913) 28 091 (839) 177 (145) −27 914 (839) −737 (−3187 to 1716) 0.56
Other, acute 5143 (563) 2682 (394) 2461 (602) 6649 (899) 3904 (517) −2745 (1007) 284 (−2017 to 2585) 0.81
Other, not acute 1456 (225) 1314 (236) −142 (317) 2111 (724) 705 (186) −1406 (757) 1264 (−358 to 2883) 0.13
Total 44 391 (1806) 7048 (879) −37 343 (1766) 45 264 (2173) 7942 (847) −31 321 (2173) −22 (−5451 to 5406) 0.99
Hospital outpatient (visits)
Cardiology 730 (59) 909 (101) 179 (114) 658 (57) 610 (78) −48 (86) 227 (−47 to 503) 0.11
Thoracic surgery 33 (8) 184 (28) 151 (27) 43 (8) 84 (17) 41 (19) 110 (46 to 177) <0.01
Other 1945 (265) 2147 (303) 202 (177) 1734 (121) 1868 (365) 134 (333) 68 (−672 to 807) 0.86
Total 2707 (273) 3240 (315) 533 (209) 2435 (139) 2561 (376) 126 (342) 407 (−378 to 1191) 0.29
Pharmaceuticals (drug categories)
ACE-inhibitors 9 (1.2) 11 (1) 2 (1) 11 (2) 12 (2) 1 (1) 2 (−1 to 6) 0.23
Antithrombotic 29 (3) 59 (18) 30 (18) 29 (2) 34 (5) 5 (8) 25 (−14 to 65) 0.21
β-blockers 15 (2) 31 (2) 16 (2) 13 (2) 27 (3) 14 (3) 2 (−4 to 9) 0.47
Spironolactone 2 (1) 5 (1) 3 (1) 3 (1) 6 (1) 3 (1) 0 (−3 to 2) 0.68
Lipid modifying 57 (12) 86 (13) 29 (9) 44 (12) 69 (14) 25 (10) 4 (−23 to 30) 0.78
Digoxin 2 (1) 3 (1) 1 (1) 2 (1) 4 (1) 2 (1) −1 (−4 to 1) 0.21
Diuretics 24 (4) 25 (2) 1 (4) 24 (3) 25 (2) 1 (3) 0 (−10 to 10) 0.99
Vitamin K antagonists 14 (2) 60 (6) 46 (6) 17 (2) 56 (7) 39 (6) 7 (−11 to 25) 0.45
Psycholeptics 0 (0) 0 (0) 0 (0) 5 (4) 11 (5) 6 (4) −6 (−13 to 2) 0.12
Antiarrythmics 2 (0) 6 (1) 4 (1) 3 (1) 6 (1) 3 (1) 1 (−2 to 4) 0.36
Analgetics* 13 (3) 16 (3) 3 (2) 28 (8) 29 (8) 1 (6) 2 (−10 to 13) 0.76
Other cardiovascular 43 (6.3) 25 (4) −18 (5) 57 (8) 24 (4) −33 (7) 15 (−2 to 33) 0.09
Other medication 256 (26) 254 (24) −2 (15) 305 (35) 300 (28) −5 (23) 3 (−51 to 57) 0.91
Total 466 (34) 581 (35) 115 (30) 541 (46) 602 (39) 61 (30) 54 (−28 to 136) 0.88
Total cost (healthcare) 48 176 (1897) 11 641 (960) −36 535 (1786) 48 864 (1786) 11 922 (1040) −36 943 (2225) 408 (−5083 to 5896) 0.89
Sick leave, weeks 1320 (278) 4424 (681) 3104 (561) 1079 (256) 3260 (645) 2181 (503) 923 (−579 to 2426) 0.23
Total costs (societal) 49 496 (1965) 16 065 (1191) −33 431 (1925) 49 943 (2334) 15 182 (1269) −34 761 (2290) 1330 (−4427 to 7086) 0.65
Values are mean costs (SE) and mean differences (95% CI).
*Includes analgetics and topical products with DDD value for joint and muscular pain.
CR, cardiac rehabilitation; DDD, defined daily doses.
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Figure 1 Cost of healthcare and sick leave before and after heart valve surgery (€). Monthly costs of healthcare and sick leave
1 year before and after heart valve surgery. Owing to the current weekly register practice. Sick leave costs are presented as
4-week months. Time 0 indicates time of surgery. Values are mean values with 95% bootstrapped CIs.
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healthcare utilisation, sick leave or costs for any of the
other categories of primary care, hospital inpatient
admissions, prescription medication or sick leave,
between the groups. We also found no statistically signiﬁ-
cant differences in either total healthcare use or total
costs €1330 (−4427 to 7086, p=0.65) between the
groups.
Although non-signiﬁcant, some tendencies were
found, including reductions in acute inpatient hospital
admissions per patient in cardiovascular, thoracic
surgery and other departments, in favour of the CR
group. We also found a non-signiﬁcant higher number
of sick leave weeks and costs per patient in the CR
group (table 2).
The total costs per patient for the year before heart
valve surgery were estimated at €49 496 (45 645 to
53 346) per patient in the CR group and €49 943
(45 367 to 54 517) in the no CR group and, respectively,
€16 065 (13 730 to 18 399) and €15 182 (12 695 to
17 670) for the year following surgery (table 3). The
main cost driver during the presurgery period was the
heart valve surgery index hospital admission, and hos-
pital inpatient admissions postsurgery. In both groups,
an increase in costs per patient was found overall for
primary healthcare visits, outpatient visits, prescription
medication and sick leave from the presurgery to post-
surgery periods, while a decrease was found across hos-
pital inpatient admission categories.
Figure 1 illustrates the monthly distribution of costs.
Following surgery, for both groups, the costs associated
with primary care visits, prescription medication and sick
leave, peaked during the ﬁrst month following discharge
and gradually returned to a level corresponding to the
12 months before surgery by the end of follow-up. Also,
costs due to inpatient admissions were highest within the
ﬁrst month postsurgery. Patients were admitted during
the ﬁrst month due to primary diagnoses, ranging from
heart failure, arrhythmia, infective endocarditis, other
infections, cancer, stroke, myocardial infarction and peri-
cardial effusion, to allergic reactions. Decreases in out-
patient visits and costs were observed immediately after
surgery, followed by an increase for the CR group, corre-
sponding to the CR participation period.
Owing to baseline differences between responders
and non-responders, we analysed the differences in pre-
surgery to postsurgery costs for non-responders (n=167)
for the categories of primary care visits €242 (146 to
337), outpatient visits €265 (−297 to 827), hospital
inpatient admissions €−37 147 (−42 221 to −32 071),
prescription medication €94 (−19 to 206), sick leave
1835 (484 to 3186) and total costs €−37 711 (−40 102 to
−29 321) for comparison with the CR and no CR groups
(data not shown).
DISCUSSION
This study investigated the cost consequences of CR in
patients undergoing heart valve surgery from a broad
analytical perspective. Overall, we found that provision
of CR appears to be cost neutral, with no differences in
total costs of healthcare or sick leave. This ﬁnding
masked a higher number of outpatient visits among CR
participants, which could only be partly explained by CR
participation, indicating that CR patients potentially sub-
stitute more expensive outpatient visits with the rehabili-
tation services offered.
No economic evaluations or cost analyses have previ-
ously investigated the economic implications of CR to
heart valve surgery patients. Difﬁculties comparing costs
across patient populations were highlighted in a system-
atic review reporting a range of costs estimated as
€1,940–€24,941 per life year gained across economic eva-
luations included.13 Among three studies conducted
alongside randomized trials and included in a recent
Cochrane review on the effect of CR to coronary artery
disease patients, two studies found no statistically signiﬁ-
cant differences in total health care costs between CR
participants and usual care, while the third reported
higher total healthcare costs associated with CR (EUR
4,280.97 more per patient).25 All studies reported
limited data on costs per patient and could not be com-
pared due to different timing and currency and are not
directly comparable to our study.
Also, two cost analyses have been conducted as part of
non-randomized studies among coronary artery disease
patients with 21 months and 5 years of follow-up.26 27
Data from these are not directly comparable to our
study due to timing of the studies. However, CR partici-
pation reduced cardiovascular hospital admissions in
both studies, and in the 5-year follow-up study, CR parti-
cipants returned to work more frequently.
In our study, we found no corresponding impact of
CR on inpatient hospital admissions or costs even
though hospital inpatient admissions were cost drivers
following surgery, which may have several explanations.
Hospital admissions to cardiovascular departments were
second to acute admissions to other departments, indi-
cating that these patients have other health problems
not inﬂuenced by CR. Additionally, the majority of hos-
pital admissions were observed during the ﬁrst month
postsurgery with the majority considered non-
preventable by CR. The difference in recurrent cardiac
events and readmissions observed for ischaemic heart
disease patients during long-term follow-up may be
partly explained by the effect of CR on risk factors,
whereas a proportion of heart valve surgery patients do
not have concomitant ischaemic heart disease.
Economic incentive models have recently been imple-
mented in some healthcare systems, where readmissions
after cardiac events are used as determinants of reim-
bursement depending on CR participation within
1 month following cardiac events.28 29 Such models may
not be suitable to heart valve surgery patients.
The difference in recurrent cardiac events and read-
missions observed for ischemic heart disease patients in
the two cost analyses compared to our study during long-
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term follow-up may be partly explained by the effect of
CR programmes on risk factors, where a proportion of
heart valve surgery patients do not have concomitant
ischemic heart disease. Therefore other outcome mea-
sures such as HRQL may be an important outcome
measure when evaluating CR to heart valve surgery
patients, particularly since HRQL has been shown to be
below the level of general population up to 6-12 months
post surgery.30 Also, heart valve surgery patients without
ischemic heart disease may beneﬁt from a specially tar-
geted programme potentially including less components
and therefore less costly than for patients with ischemic
heart disease. We found that, while all patients in our
sample participated in physical exercise training, a
varying proportion of patients in clinical practice
received other components of the CR programme, as
recommended.7 8 17 An area for future research would
be to evaluate different CR programmes aimed at these
patients. In Denmark, part of the CR programme (eg,
physical exercise training) can be conducted in cardiovas-
cular outpatient hospital settings, but also in other
medical departments or departments of thoracic surgery,
which explains why the increase in visits from presurgery
to postsurgery associated with CR participation was not
solely reﬂected in cardiovascular outpatient visits. The
number of outpatient visits due to CR in our study was
much lower than expected given current recommenda-
tions and partly reﬂects lack of information on the
number of visits conducted in municipalities, albeit the
majority of patients participated in a shared or full hos-
pital-based CR programme. However, low adherence has
been reported formerly. In a recent Danish study, con-
ducted at a large Danish university hospital, of 266
cardiac surgery patients, 112 (42%) did not complete
CR, consisting of a 8-week course with 1-h biweekly ses-
sions, with non-completion deﬁned as attendance ≤75%
of sessions, 80 patients (30%) completed all sessions, and
74 patients (28%) referred to CR never joined. A quarter
of all patients were readmitted within 8 weeks post
surgery, and readmission was found to be the strongest
predictor of non-completion CR.31 Compared to our
study, data on CR attendance was recorded in a database,
indicating a high participation rate but low CR adherence
among these patients in Denmark due to particularly
high readmission rates. Even higher readmission rates
were subsequently reported in Denmark following heart
valve surgery speciﬁcally (n=867) with 26% of the popula-
tion readmitted within 30 days and 56% having at least
one readmission during 12 months follow-up post dis-
charge.30 Higher CR attendance might potentially have
increased the costs for the CR group and/ or have substi-
tuted costs in other cost categories and thereby change
the overall ﬁndings. An important area for future
research is to compare CR programmes of different dur-
ation and intensity for this group of patients from both a
clinical and an economic perspective.
Although the difference was not signiﬁcant, in our
study, CR participants were on sick leave for a longer
period compared to non-participants, incurring higher
costs. In some studies, faster return to work among
cardiac patients enrolled in a CR programme has been
demonstrated.10 32 A French study including patients
after acute ST-segment elevation myocardial infarction
found no effect of CR on return to work and, addition-
ally, CR participants returned to work later than non-
participants.11 We included a nationwide cohort of
patients with only a marginal difference in the employ-
ment rates of responders and non-responders, and in
which a high number of patients had retired by the time
of follow-up. The low employment rate illustrates that
sick leave and return to work may not be important out-
comes in CR studies among heart valve surgery patients.
However, looking at the effect of CR among work-active
cardiac patients would be relevant to investigate if CR
participation contributes to patients remaining on sick
leave longer than expected.
We included heart valve surgery patients broadly, even
though healthcare utilisation, complications and costs of
care have been shown to differ across type of surgery.33
The difﬁculties of implementing CR recommendations
in clinical practice highlight the importance of supple-
menting the results of randomised trials with economic
data from well-performed observational studies con-
ducted from a broad perspective. Our study provides
high external validity and illustrates what happens in a
real-life setting without exclusion criteria, with national
variation in content and cost of CR provision, and
imperfect CR uptake and adherence, based on wide CR
recommendations. However, this study provides compar-
ably lower internal validity due to less detailed patient-
level information on CR services received.
Until further studies are conducted, CR can be pro-
vided to heart valve surgery patients based on recommen-
dations for patients with ischaemic heart disease, since it
imposes no signiﬁcant additional costs to a national
healthcare system. However, we recommend that studies
of the beneﬁts of CR on patient-reported outcomes, for
example, HRQL, preferably as part of a formal economic
evaluation, be conducted to provide evidence for or
against CR provision, speciﬁcally to heart valve surgery
patients, from an economic perspective. Additionally, a
proportion of patients without concomitant ischaemic
heart disease may need a specialised CR programme.
Strengths and limitations
The main strength is that we included a national cohort
of consecutive unselected patients with minor baseline
differences between CR participants versus non-
participants and complete follow-up. Owing to the
minor baseline differences, a difference-in-difference
design was employed to overcome the limitation that
our study was not randomised. However, residual con-
founding factors cannot be deﬁnitely excluded. On the
other hand, unlike an unblinded experiment, this study
design has not inﬂuenced the behaviour of the patients,
including healthcare utilisation.
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Another strength is the high survey response rate.
Owing to baseline differences between responders and
non-responders, we compared presurgery and postsur-
gery healthcare use and costs across non-responders, CR
participants and non-participants. For non-responders
compared to the other groups, for sick leave, the cost
difference from presurgery to postsurgery was smaller
and, for primary care, the difference was larger. No dif-
ferences were observed across the remaining cost cat-
egories. However, the lack of self-reported information
on CR participation among non-responders is important
to consider when addressing generalisability.
Our study has limitations. The major limitation in this
study is, that we do not have exact detailed information
about the duration of the CR programmes and number
of sessions attended since this information could not be
obtained from self-reported data due to the risk of recall
bias using a retrospective design, and also complete and
valid register based data on municipality-based CR pro-
grammes are not available in Denmark. Additionally,
our study could not be reported as a cost-effectiveness/
cost-utility study, since we did not have clinical or
patient-reported quality of life outcomes for the groups
compared.
Also, register data are subject to bias due to misclassiﬁ-
cations and different deﬁnitions used over time. The val-
idity of our study is considered high due to the short
period of two years. Finally, we did not have information
on sick leave within the ﬁrst two weeks following heart
valve surgery.
CONCLUSIONS
CR, as provided in Denmark, after heart valve surgery,
can be considered cost neutral. CR participation is asso-
ciated with more outpatient visits but may reduce other
more expensive outpatient visits. Further studies should
investigate the beneﬁts of CR on heart valve surgery
patient-reported outcomes, for example, HRQL, as part
of a formal cost-utility analysis.
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